It depends on the standard you follow. As of September 2026, ANI Pharmaceuticals, Inc. (ANIP) passes 4 of 5 published Shariah screening standards checked by Maz Vantage: it passes AAOIFI, S&P Global, Dow Jones and MSCI, and fails FTSE.
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 19.3% / 30% · (Cash+Inv) / Mkt Cap (36m) 28.3% / 30% · Interest income / Revenue 1.56% / 5% | Pass |
| S&P Global | Debt / Mkt Cap (36m) 19.3% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 28.3% / 33% · Receivables / Mkt Cap (36m) 19.8% / 49% · Interest income / Revenue 1.56% / 5% | Pass |
| Dow Jones | Debt / Mkt Cap (24m) 19.3% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 28.3% / 33.33% · Receivables / Mkt Cap (24m) 19.8% / 33.33% · Interest income / Revenue 1.56% / 5% | Pass |
| MSCI | Debt / Avg Assets (4Q) 21.6% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 23.8% / 33.33% · Receivables / Avg Assets (4Q) 18.8% / 33.33% · Interest income / Revenue 1.56% / 5% | Pass |
| FTSE | Debt / Total Assets 19.0% / 33.33% · (Cash+ST Inv) / Total Assets 27.8% / 33.33% · (Cash+Recv) / Total Assets 47.3% / 33.33% · Interest income / Revenue 1.56% / 5% | Fail |
It depends on the standard you follow. As of September 2026, ANI Pharmaceuticals, Inc. (ANIP) passes 4 of 5 published Shariah screening standards checked by Maz Vantage: it passes AAOIFI, S&P Global, Dow Jones and MSCI, and fails FTSE.
Yes. ANI Pharmaceuticals, Inc. is within every AAOIFI limit: debt and interest-bearing cash and investments under 30% of its 36-month average market cap, and interest income under 5% of revenue.
About 1.56% of each dividend: ANI Pharmaceuticals, Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.
ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) is a Healthcare company (Drug Manufacturers - Specialty & Generic) with a market capitalization of $1.6B. The Maz Rating grades it against the other companies in its sector.
ANI Pharmaceuticals, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $69.99, ANI Pharmaceuticals, Inc. trades at 13.5x trailing earnings, 1.5x sales and 2.3x book value, with an EV/EBITDA of 5.4. Over the last twelve months it generated about $1.0B of revenue and $118M of net income. It runs a gross margin of 67.8%, an operating margin of 17.3% and a net margin of 11.2%. It shows return on equity of 20.0%, return on invested capital of 10.5% and a free cash flow yield of 11.1%. On the balance sheet: a debt-to-equity ratio of 0.47 and a current ratio of 2.75. Over the past 52 weeks the share price ranged from $67.14 to $87.76, with a beta of 0.47.
ANI Pharmaceuticals, Inc. does not currently pay a dividend.
10 Wall Street analyst ratings cover the stock: 6 Buy and 4 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic pharmaceutical products in the United States and internationally. The company provides injectables, softgel capsules, and Cortrophin gel, as well as ILUVIEN and YUTIQ products. It also manufactures oral solid dose products, semi-solids, liquids, topicals, controlled substances, and potent products. The company serves its products to national wholesalers, specialty pharmacies, retail pharmacy chains, distributors, mail order houses, group purchasing organizations, and hospitals and healthcare providers. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.